...
首页> 外文期刊>Clinical neuropharmacology >Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study.
【24h】

Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study.

机译:曲唑酮用于治疗由5-羟色胺再摄取抑制剂引起的性功能障碍:一项开放性研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

INTRODUCTION: Treatment with selective serotonin reuptake inhibitors (SSRIs) may lead to sexual dysfunction in up to 70% of patients. Because the SSRIs are widely used antidepressants, their propensity to cause sexual dysfunction may affect compliance with therapy and ultimately treatment success. To date, the pathophysiological mechanism of sexual dysfunction caused by SSRIs remains incompletely understood, and the management of SSRIs-induced sexual dysfunction remains unsatisfactory. We suggest that medications that antagonize serotonin receptors such as trazodone may improve sexual dysfunction reverting the stimulation of serotonin receptors by SSRIs. OBJECTIVE: The aim of this study was to investigate the efficacy of trazodone administration in the management of SSRI-induced sexual dysfunction. METHODS: Twenty patients (11 men/9 women) with SSRIs-induced sexual dysfunction were recruited for the study. Trazodone was added to the existing SSRI regimen in open-label fashion for 4 weeks (50 mg for the first week increased to 100 mg until the completion of the study). The improvement in the 4 dimensions of sexual function (desire, erection or lubrication problems in women, ejaculation or orgasm in women, and overall satisfaction by both sexes) was the primary outcome measure of the study. RESULTS: Fifteen subjects completed the study. Results indicated improvement in sexual function and overall clinical improvement (depression, anxiety) as well. Specific gender differences indicated improvement in erectile performance in men and lubrication in women. No correlations were noted between clinical improvement of depression or anxiety and improvement in sexual dysfunction. CONCLUSIONS: The 5-HT2 antagonist, trazodone, may be beneficial in the management of SSRI-induced sexual dysfunction. Large-scale, placebo-controlled, double-blind studies with 5-HT2 antagonists are required to substantiate these preliminary observations.
机译:简介:选择性5-羟色胺再摄取抑制剂(SSRI)的治疗可能导致多达70%的患者出现性功能障碍。由于SSRIs是广泛使用的抗抑郁药,它们引起性功能障碍的倾向可能会影响对治疗的依从性,并最终影响治疗的成功。迄今为止,由SSRI引起的性功能障碍的病理生理机制仍未完全理解,对SSRI引起的性功能障碍的治疗仍不令人满意。我们建议拮抗血清素受体(如曲唑酮)的药物可能会改善性功能障碍,从而恢复SSRI对血清素受体的刺激。目的:本研究的目的是探讨曲唑酮治疗SSRI引起的性功能障碍的疗效。方法:招募了20例SSRIs引起的性功能障碍的患者(11例男性/ 9例女性)。将曲唑酮以开放标签的方式添加到现有的SSRI方案中,持续4周(第一周的50 mg增加至100 mg,直到研究完成)。性功能的四个方面的改善(女性的欲望,勃起或润滑问题,女性的射精或性高潮以及男女双方的总体满意度)是该研究的主要结局指标。结果:15名受试者完成了研究。结果表明性功能得到改善,整体临床症状也得到改善(抑郁,焦虑)。特定的性别差异表明,男性的勃起性能得到改善,女性的润滑得到改善。在抑郁症或焦虑症的临床改善与性功能障碍改善之间未发现相关性。结论:5-HT2拮抗剂曲唑酮可能有助于治疗SSRI引起的性功能障碍。需要使用5-HT2拮抗剂进行大规模,安慰剂对照,双盲研究,以证实这些初步观察结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号